Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The Middle Child in Heart Failure: Heart Failure with Mid-Range Ejection Fraction (40–50%)

Open access
Lam, Carolyn S.P., Solomon, Scott D.·2014·European Journal of Heart Failure

Abstract

The 'middle child', classically the second in a family of three siblings, often feels neglected. While lavish attention is generally paid to the first born and the baby, the middle child is typically squeezed between these two and has trouble finding his/her 'niche' in the family. In short, the older child gets all the awards, the younger gets all the love, and the middle gets nothing The analogy within the heart failure (HF) family is striking: The big brother—HF with reduced ejection fraction (HFrEF)—was the first born in HF clinical trials, with the vast majority of early HF trials being restricted to patients with LVEF <35–40%.1, 2 This is the group for which we have accumulated the most therapeutic evidence, including effective pharmacological and device therapies that have led to impressive improvements in survival. The youngest sibling, HF with preserved EF (HFpEF; defined in current guidelines using an EF cut-off of ≥50%1, 2) was conceived as 'diastolic HF' barely two decades ago. While initially regarded by some as an 'illegitimate' child, this syndrome has grown to be accepted as true HF, recognized as affecting half the HF population, and projected to become the predominant form of HF in the future.3 While the attention given to HFpEF has increased exponentially, with more and larger trials being focused on this patient population, there is still no effective evidence-based therapy.4 The specific LVEF cut-off for HFpEF that has been advocated by guidelines, and modified slightly by clinical trials (which have mostly chosen 45% rather than 50%), has not been based on any real pathophysiologic or outcomes data advocating for one LVEF cut-off versus the other. However, by defining a cut-off for HFpEF that is higher than that used to define the HFrEF population, we have necessarily left a gap in the 40–50% middle range, leaving the 'middle child' of HF neglected. In the American College of Cardiology/American Heart Association guidelines,2 this range is referred to as an 'intermediate group', and dismissed with treatment for underlying risk factors/co-morbidities and with medical therapies similar to those used for HFrEF. Similarly, the European Society of Cardiology guidelines1 refer to HF with EF 35–50% as a 'grey area' to be regarded as mild systolic dysfunction (i.e. a lesser big brother). We fully acknowledge, along with others,5 that LVEF is not an ideal parameter to stratify patients with HF. For one, there is inherent variability in the estimation of LVEF from echocardiography, which can potentially lead to misclassification. Other measures of systolic function such as myocardial deformation imaging may be better parameters.6 Yet, clinical trials historically using LVEF to stratify HF have clearly demonstrated its utility in determining outcome benefit of HF therapies: trials of renin–angiotensin–aldosterone system blockade showed improved survival in HFrEF but not in HFpEF. Any classification that can guide treatment may be deemed useful in clinical practice. Until we can effectively tease apart pathophysiological subtypes in HF using a different classification system of proven utility for clinical management and targeted therapy, we are left with our current system of using LVEF. The existence of an 'evidence gap' for the patients with mid-range LVEF occurred due to historical development of HF trials rather than due to a strong pathophysiological basis for a third entity in HF. Nonetheless, we refer to this neglected middle child of HF as HF with mid-range EF (HFmEF) herein. The recognition of this group of patients with mid-range EF does not imply that patients inevitably progress from HFpEF to HFmEF then HFrEF; in fact ample evidence exists that HFpEF and HFrEF are distinct syndromes with fundamental pathophysiological differences, and rarely transition from one to the other except in the presence of CAD.4 Our purpose is to summarize available data regarding this patient group and discuss the gaps in evidence that need to be addressed. There are limited data regarding the prevalence of HFmEF, since most epidemiological HF studies stratified patients above and below EF 50%; most HFrEF clinical trials included patients with EF <35–40% exclusively; whereas HFpEF clinical trials such as Aldo-DHF7 and RELAX8 used an EF cut-off of 50%, while TOPCAT,9 PARAMOUNT,10 and I-PRESERVE11 used a cut-off of 45% in their inclusion criteria. Nonetheless, a handful of HF studies included a broad range of EF and reported the distribution of EF within their large study populations: in the CHARM Program,12 a unimodal bell-shaped distribution was observed across the range of EF, indicating a substantial proportion of patients in the 'middle band' of EF 40–50% (Figure 1A). In fact, 1295 of 7955 (17%) patients in CHARM had EF 43–52%. However, in the OPTIMIZE Registry of patients with acute HF,13 as well as the community-based study from Olmsted County,14 a bimodal distribution of EF was seen, with the nadir at E

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.159

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Lam, C. S. P., & Solomon, S. D.
Venue
European Journal of Heart Failure
Published
2014-09-11
Volume
16
Issue
10
Pages
1049-1055
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2159700625
Cited by
217
References
5
FWCI
12.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.